News from kyowa kirin, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 18, 2022, 10:31 ET La Jolla Institute renews longtime collaboration with Kyowa Kirin, Inc.

La Jolla Institute for Immunology (LJI) and Kyowa Kirin, Inc. (KKNA), a wholly-owned subsidiary of Kyowa Kirin Co., Ltd (Kyowa Kirin, TSE: 4151), a...

Sep 27, 2021, 09:00 ET Kyowa Kirin North America Appoints Paula Soteropoulos to Board of Directors

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, welcomed Paula...
Kyowa Kirin Launches New Efforts to Educate and Engage Physicians and Patients with Rare Forms of Cutaneous T-Cell Lymphoma About Treatment with POTELIGEO® (mogamulizumab-kpkc)

Sep 23, 2021, 08:00 ET Kyowa Kirin Launches New Efforts to Educate and Engage Physicians and Patients with Rare Forms of Cutaneous T-Cell Lymphoma About Treatment with POTELIGEO® (mogamulizumab-kpkc)

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, today announced the...

Sep 13, 2021, 09:00 ET Kyowa Kirin to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Phase 2 Study at The European Academy of Dermatology and Venereology 30th Congress

Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, "Kyowa Kirin"), a global specialty pharmaceutical company creating innovative...

Jul 22, 2021, 14:12 ET New Publication Offers Insight into POTELIGEO® (mogamulizumab-kpkc) Treatment Response in Cutaneous T-cell Lymphoma Patients with Varying Levels of Blood Involvement

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, today announced new data ...

May 04, 2021, 15:30 ET Kyowa Kirin North America Announces Key Executive Appointments in R&D and Medical Affairs As Late-Stage Assets Move Toward Key Milestones

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, recently named Ernesto...
Kyowa Kirin Integrates North America Businesses in Support of Company's 2030 Vision and Rapid Growth Trajectory

Mar 31, 2021, 16:30 ET Kyowa Kirin Integrates North America Businesses in Support of Company's 2030 Vision and Rapid Growth Trajectory

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, today announced a key...

Dec 06, 2020, 07:00 ET New Data from MAVORIC Trial Sheds Light on Key Characteristics of Long-term POTELIGEO® (mogamulizumab-kpkc) Responders with Specific Subtypes of Cutaneous T-cell Lymphoma

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, today announced data...
Kyowa Kirin North America Announces Recipients of Patient Education Grants to Address Disparities for African-American Patients with Cutaneous T-Cell Lymphomas (CTCL)

Oct 20, 2020, 10:00 ET Kyowa Kirin North America Announces Recipients of Patient Education Grants to Address Disparities for African-American Patients with Cutaneous T-Cell Lymphomas (CTCL)

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, announced the Cutaneous...
Kyowa Kirin Announces Patient Education Grant Program to Address Disparities for African-American Patients with Cutaneous T-Cell Lymphomas (CTCL)

Jul 13, 2020, 10:00 ET Kyowa Kirin Announces Patient Education Grant Program to Address Disparities for African-American Patients with Cutaneous T-Cell Lymphomas (CTCL)

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, is establishing a...

May 26, 2020, 17:15 ET Impact of Baseline Dyskinesia on Safety and Efficacy of NOURIANZ® (istradefylline) in Patients with Parkinson's Disease Presented During "Virtual" European Academy of Neurology Meeting

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, today announces the...

Jan 31, 2020, 09:00 ET Kyowa Kirin Announces Final Safety Data of POTELIGEO® (mogamulizumab-kpkc) from MAVORIC Trial

Kyowa Kirin, Inc., (Kyowa Kirin, TSE: 4151) announces the final safety data from the MAVORIC (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In...